Search Results

You are looking at 1 - 8 of 8 items for :

  • "pasireotide" x
Clear All
Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

-generation somatostatin analogs in patients with AIP mutations, the role of other agents such as the GH receptor antagonist pegvisomant has been described in those with AIP mutations ( 14 ). Pasireotide is a newer somatostatin analog that is approved for use in

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

adenomas were significantly more frequent in the low AIP-IHC group. Sparsely granulated adenomas have previously been shown to be associated with lower responses to octreotide/lanreotide and better responses to pasireotide and they predominate in AIP mut

Open access

Julie M Silverstein

Biopharmaceuticals Inc, Basking Ridge, NJ, USA), and pasireotide LAR are the currently available SSAs approved by the Food and Drug Administration for the treatment of patients with acromegaly (32, 33, 34, 35) . Approximately 50% of patients with acromegaly achieve

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

) and second generation (pasireotide) somatostatin analogs (SSa), and the rationale of the use of radiolabeled-SSa for diagnostic imaging and PRRT ( 111 In-pentreotide, 177 Lu-DOTA, 90 Y-DOTA, 68 Ga-DOTA) ( 8 , 9 ). Herein we report on the

Open access

K E Lines, R P Vas Nunes, M Frost, C J Yates, M Stevenson and R V Thakker

Research 2012 72 5060 – 5068 . ( doi:10.1158/0008-5472.CAN-12-1821 ) 24 Walls GV Stevenson M Soukup BS Lines KE Grossman AB Schmid HA Thakker RV. Pasireotide therapy of multiple endocrine neoplasia type 1-associated

Open access

Paula Bruna Araujo, Leandro Kasuki, Carlos Henrique de Azeredo Lima, Liana Ogino, Aline H S Camacho, Leila Chimelli, Márta Korbonits and Monica R Gadelha

pituitary surgeries, and the pathology revealed a SG somatotropinoma. Due to resistance to combined first-generation SA and CAB therapy, the patient was started on pasireotide LAR, which resulted in disease control. The missense AIP VUS A299V (c.896C > T

Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

Ravichandran S Strosberg JR Wolin EM . Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors . OncoTargets and Therapy 2017 10 3177 – 3186 . ( https://doi.org/10.2147/OTT.S128547 ) 25 Grillo F Florio T Ferrau

Open access

E T Aristizabal Prada and C J Auernhammer

pasireotide ( 125 ). The Ras–Raf–MEK–ERK pathway is a highly complex network interacting with other crucial cellular pathways such as the PI3K–Akt–mTOR pathway ( 65 ). Inhibition of mTORC1 causes compensatory upregulation of the MAPK pathway ( 132 , 133